scholarly journals Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma

Oncotarget ◽  
2016 ◽  
Vol 7 (23) ◽  
pp. 35241-35256 ◽  
Author(s):  
Takashi Eguchi ◽  
Kyuichi Kadota ◽  
Jamie Chaft ◽  
Brent Evans ◽  
John Kidd ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Lung Adenocarcinoma ◽  
Mortality Risk ◽  
Cell Cycle Progression ◽  
Stage I ◽  
Cycle Progression ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Resected Stage

Validation of a cell cycle progression score for 5-year mortality risk in patients with stage I non-small cell lung cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 7522-7522
Author(s):  
Takashi Eguchi ◽  
Kadota Kyuichi ◽  
Brent Evans ◽  
Camelia S. Sima ◽  
Thaylon Davis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Mortality Risk ◽  
Cell Cycle Progression ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cycle Progression ◽  
A Cell

Protein arginine methyltransferase-5  Selective Inhibitor Enhances Therapeutic Effects of Cisplatin on Lung Cancer Cells

2020 ◽  
Author(s):  
Khuloud Bajbouj ◽  
Rakhee K. Ramakrishnan ◽  
Maha Saber-Ayad ◽  
Hany A. Omar ◽  
Narjes Saheb Sharif-Askari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Epithelial Cells ◽  
Lung Adenocarcinoma ◽  
Cell Cycle Progression ◽  
Cycle Progression ◽  
Arginine Methyltransferase ◽  
Bronchial Epithelial ◽  
Adenocarcinoma Cell ◽  
Functional Pathways

Abstract Background Lung cancer is the most common cancer globally. Protein arginine methyltransferase 5 (PRMT5) is identified to be involved in gene transcriptional regulation and cell division. PRMT5 is highly expressed in lung adenocarcinoma, hepatocellular carcinoma, and melanoma, raising evidence that PRMT5 might be involved in tumorigenesis. The aim of this study is to examine potential selective anti-neoplastic activity of PRMT5 inhibitor, Arginine methyltransferase inhibitor 1 (AMI-1) and cisplatin on lung adenocarcinoma. Methods Effect of AMI-1 on PRMT5 activity inhibition in lung adenocarcinoma cell line, A549, in response to standard chemotherapeutic agent, cisplatin, was assessed. Bioinformatic analyses were carried out to identify the prognostic value of PRMT5 and its major functional pathways in lung adenocarcinoma. Cell viability, PMRT5 protein levels, extent of cell migration, survival of cancer cells, and cell cycle progression and apoptosis were examined. Drug combination was also evaluated in human bronchial epithelial cells (HBEpC). Results Bioinformatics identified apoptosis, DNA damage, and cell cycle progression as the main PRMT5 associated functional pathways, and survival analysis linked the increased PRMT5 gene expression to worse overall survival. Combination treatment with 10 µM AMI-1 and of Cisplatin significantly reduced viable cell percentages. Cell cycle arrest in A549 cells was evident after AMI-1, which was reinforced after combination treatment. Apoptosis was observed after treatment with both drugs. Western blot analysis showed reduction in demethylation histone 4, a PRMT5- downstream target, after treatment with AMI-1 alone or in combination with cisplatin. While combination approach tackled lung cancer cell survival, it exhibited cytoprotective abilities on normal epithelial cells. Finally, treatment with both drugs led to a decreased cell migration rate. Conclusions This study highlights evidence of novel selective antitumor additive activity of AMI-1 in combination with cisplatin in lung adenocarcinoma cells. Survival of normal bronchial epithelial cells was not affected by using AMI-1.

scholarly journals EGFR-ERK induced activation of GRHL1 promotes cell cycle progression by up-regulating cell cycle related genes in lung cancer

2021 ◽  
Vol 12 (5) ◽  
Author(s):  
Yiming He ◽  
Mingxi Gan ◽  
Yanan Wang ◽  
Tong Huang ◽  
Jianbin Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Cell Cycle Progression ◽  
Potential Role ◽  
Target Genes ◽  
Nuclear Translocation ◽  
Phosphorylation Site ◽  
Promoter Regions ◽  
Cycle Progression

AbstractGrainyhead-like 1 (GRHL1) is a transcription factor involved in embryonic development. However, little is known about the biological functions of GRHL1 in cancer. In this study, we found that GRHL1 was upregulated in non-small cell lung cancer (NSCLC) and correlated with poor survival of patients. GRHL1 overexpression promoted the proliferation of NSCLC cells and knocking down GRHL1 inhibited the proliferation. RNA sequencing showed that a series of cell cycle-related genes were altered when knocking down GRHL1. We further demonstrated that GRHL1 could regulate the expression of cell cycle-related genes by binding to the promoter regions and increasing the transcription of the target genes. Besides, we also found that EGF stimulation could activate GRHL1 and promoted its nuclear translocation. We identified the key phosphorylation site at Ser76 on GRHL1 that is regulated by the EGFR-ERK axis. Taken together, these findings elucidate a new function of GRHL1 on regulating the cell cycle progression and point out the potential role of GRHL1 as a drug target in NSCLC.

scholarly journals Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Jing Du ◽  
Weiwei Chen ◽  
Lijuan Yang ◽  
Juanjuan Dai ◽  
Jiwei Guo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Cancer Cells ◽  
Signaling Pathway ◽  
Cell Cycle Progression ◽  
Lung Cancer Cells ◽  
Human Lung Cancer ◽  
Cycle Progression ◽  
Shh Signaling ◽  
Shh Pathway

Abstract Deregulated Sonic Hedgehog (SHH) pathway facilitates the initiation, progression, and metastasis of Non-small cell lung cancer (NSCLC), confers drug resistance and renders a therapeutic interference option to lung cancer patients with poor prognosis. In this study, we screened and evaluated the specificity of a Chinese herb Scutellariabarbata D. Don extraction (SBE) in repressing SHH signaling pathway to block NSCLC progression. Our study confirmed that aberrant activation of the SHH signal pathway conferred more proliferative and invasive phenotypes to human lung cancer cells. This study revealed that SBE specifically repressed SHH signaling pathway to interfere the SHH-mediated NSCLC progression and metastasis via arresting cell cycle progression. We also found that SBE significantly sensitized lung cancer cells to chemotherapeutic agent DDP via repressing SHH components in vitro and in vivo. Mechanistic investigations indicated that SBE transcriptionally and specifically downregulated SMO and consequently attenuated the activities of GLI1 and its downstream targets in SHH signaling pathway, which interacted with cell cycle checkpoint enzymes to arrest cell cycle progression and lead to cellular growth inhibition and migration blockade. Collectively, our results suggest SBE as a novel drug candidate for NSCLC which specifically and sensitively targets SHH signaling pathway.

scholarly journals Molecular Mechanisms Underlying Yatein-Induced Cell-Cycle Arrest and Microtubule Destabilization in Human Lung Adenocarcinoma Cells

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1384 ◽  
Author(s):  
Shang-Tse Ho ◽  
Chi-Chen Lin ◽  
Yu-Tang Tung ◽  
Jyh-Horng Wu
Keyword(s):  
Cell Cycle ◽  
Antitumor Activity ◽  
Lung Adenocarcinoma ◽  
Cell Cycle Progression ◽  
Molecular Mechanisms ◽  
Human Lung ◽  
Microtubule Dynamics ◽  
Cycle Progression ◽  
Human Lung Adenocarcinoma

Yatein is an antitumor agent isolated from Calocedrus formosana Florin leaves extract. In our previous study, we found that yatein inhibited the growth of human lung adenocarcinoma A549 and CL1-5 cells by inducing intrinsic and extrinsic apoptotic pathways. To further uncover the effects and mechanisms of yatein-induced inhibition on A549 and CL1-5 cell growth, we evaluated yatein-mediated antitumor activity in vivo and the regulatory effects of yatein on cell-cycle progression and microtubule dynamics. Flow cytometry and western blotting revealed that yatein induces G2/M arrest in A549 and CL1-5 cells. Yatein also destabilized microtubules and interfered with microtubule dynamics in the two cell lines. Furthermore, we evaluated the antitumor activity of yatein in vivo using a xenograft mouse model and found that yatein treatment altered cyclin B/Cdc2 complex expression and significantly inhibited tumor growth. Taken together, our results suggested that yatein effectively inhibited the growth of A549 and CL1-5 cells possibly by disrupting cell-cycle progression and microtubule dynamics.

scholarly journals Knockdown of COPS3 Inhibits Lung Cancer Tumor Growth in Nude Mice by Blocking Cell Cycle Progression

2017 ◽  
Vol 8 (7) ◽  
pp. 1129-1136 ◽  
Author(s):  
Jianan Pang ◽  
Xu Yan ◽  
He Cao ◽  
Lei Qian ◽  
Hua He ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Tumor Growth ◽  
Nude Mice ◽  
Cell Cycle Progression ◽  
Cycle Progression ◽  
Cancer Tumor

scholarly journals Stimulation of ROS Generation by Extract of Warburgia ugandensis Leading to G0/G1 Cell Cycle Arrest and Antiproliferation in A549 Cells

Antioxidants ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 1559
Author(s):  
Yong-Li Zhang ◽  
Gui-Lin Chen ◽  
Ye Liu ◽  
Xiao-Cui Zhuang ◽  
Ming-Quan Guo
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Cell Cycle Progression ◽  
A549 Cells ◽  
Small Cell ◽  
G1 Phase ◽  
Ros Generation ◽  
Small Cell Lung ◽  
Cycle Progression ◽  
Intracellular Ros

Warburgia ugandensis Sprague (WU) is a traditional medicinal plant used for the treatment of various diseases, including cancer, in Africa. This study aimed to evaluate the anti-non-small cell lung cancer (NSCLC) activities of WU against A549 cells and to reveal potential molecular mechanisms. The cytotoxicity of various WU extracts was evaluated with HeLa (cervical cancer), HepG2 (liver cancer), HT-29 (colorectal cancer), and A549 (non-small cell lung cancer) cells by means of Sulforhodamine B (SRB) assay. Therein, the dimethyl carbonate extract of WU (WUD) was tested with the most potent anti-proliferative activity against the four cancer cell lines, and its effects on cell viability, cell cycle progression, DNA damage, intracellular reactive oxygen species (ROS), and expression levels of G0/G1-related proteins in A549 cells were further examined. First, it was found that WUD inhibited the proliferation of A549 cells in a time- and dose-dependent manner. In addition, WUD induced G0/G1 phase arrest and modulated the expression of G0/G1 phase-associated proteins Cyclin D1, Cyclin E1, and P27 in A549 cells. Furthermore, WUD increased the protein abundance of P27 by inhibiting FOXO3A/SKP2 axis-mediated protein degradation and also significantly induced the γH2AX expression and intracellular ROS generation of A549 cells. It was also found that the inhibitory effect of WUD on the proliferation and G0/G1 cell cycle progression of A549 cells could be attenuated by NAC, a ROS scavenger. On the other hand, phytochemical analysis of WUD with UPLC-QTOF-MS/MS indicated 10 sesquiterpenoid compounds. In conclusion, WUD exhibited remarkable anti-proliferative effects on A549 cells by improving the intracellular ROS level and by subsequently modulating the cell proliferation and G0/G1 cell cycle progression of A549 cells. These findings proved the good therapeutic potential of WU for the treatment of NSCLC.

Sign in / Sign up

Export Citation Format

Share Document